A New Type of Medicine: Biotherapeutics Usher in a New Era

DSP

Why More Product Upstream Creates New Pressure Downstream

Pharma's Almanac

Allogeneic CAR-T

Can Allogeneic Cell Therapy Solve the CAR-T Access Problem?

Pharma's Almanac

BsAbs in Oncology

Bispecific Antibodies Move Into the Heme-Onc Mainstream

David Alvaro, Ph.D.

Pharma's Almanac

Biosimilars

The Global Division of Labor Behind the Coming Oncology Biosimilar Wave

Pharma's Almanac

iPSCs

For iPSC Therapies, Manufacturing Consistency May Mean Preserving Function

Pharma's Almanac

Single-Use

The Changing Economics of Single-Use Biomanufacturing

Pharma's Almanac

Biologics Platform

Platform-Based Drug Substance Development: Applying Prior Knowledge Across Modalities

Mathias Kahl

IDT Biologika

Productivity

The Next Productivity Leap in Mammalian Cell Culture

Pharma's Almanac

Capacity

Is the Bioreactor Arms Race Over?

David Alvaro, Ph.D.

Pharma's Almanac

Lipase Risk

An Integrated Analytical Approach to Lipase Risk Management in Biologics Development

Kyeyeon Hur, Ph.D.; Jimin Kim, Ph.D.; Minjeong Lee; Soojeong Oh; Woojung Jun

Samsung Biologics